Abstract: The present invention concerns lipid vesicles having dimethylamides as their primary structural lipid. Preferred dimethylamides useful in the invention are DMATO and DMASO oils. These vesicles are useful as carriers of water immiscible oily material such as fungicides. In a most preferred aspect, the invention has DMATO vesicles with TCMTB as a fungicide in trapped therein. The vesicles can be made rapidly and provide aqueous dispersion of these materials without the need for additional organic solvents.

Abstract: An amphipathic compound, which includes a succinic acid moiety and an amino acid moiety and is designed so as to form a stable unilayer liposome, and a negatively charged liposome comprising said amphipathic compound as a membrane-component are disclosed. The amphipathic compound of the present invention gives liposomes which minimize the leakage of a drug encapsulated therein and scarcely undergo association, aggregation or precipitation.

Abstract: The present invention relates to a composition based on hydrated lipidic lamellar phases or on liposomes.In this composition, pregnenolone or a pregnenolone ester, such as, in particular, pregnenolone acetate, sulfate or palmitate, is at least partially incorporated in the said hydrated lipidic lamellar phases or the said liposomes.This composition can be applied in particular in the cosmetic or pharmaceutical sector, especially the dermatological sector, for the preparation of compositions with regenerating or revitalizing activity.

Abstract: The present invention relates to a pharmaceutical pellet composition having a core element including at least one highly soluble active ingredient and a core coating which is partially soluble at a highly acidic pH. The pharmaceutical composition provides a slow release of active ingredient at a highly acidic pH and provides a constant, relatively faster rate of release at a more alkaline pH such as that of the intestine. Oral administration of the pharmaceutical pellet composition of the present invention to a patient is effective to deliver to the blood levels of active ingredient within the therapeutic range and to maintain such levels over an extended period of time.

Abstract: Compositions based on hydrated lipidic lamellar phases or liposomes are disclosed containing at least in part at least one ecdysteroid or ecdysteroid derivative, in particular ecdysterone, or a plant or animal extract containing the said ecdysteroid or ecdysteroid derivative. Cosmetic or pharmaceutical compositions can be prepared as well as compositions for sericulture or a phytosanitary composition.

Abstract: A pH-dependent sustained release pharmaceutical pellet composition and a method of administering the same to a patient at a predetermined dosage and interval, said pellet composition comprising: a core element containing a therapeutically effective amount of theophylline, xanthine or a derivative thereof as the active ingredient and a coating on said core element which comprises the following components:(a) at least 40% of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.

Abstract: An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 2:1. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between about 50-250 nm. The composition has stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infection than prior amphotericin B formulations.

Abstract: Antiparasitic agents constituted by a siderophore substance including at least one hydroxamate group, at least one peptide bond, and having a molecular weight of less than 1,000 D, e.g. aerobactin. A method of isolating antiparasitic agents by purification from the supernatant of a culture of an appropriate bacteria such as pathogenic enterobacteria applicable as antiparasitic agents, in particular as antimalarial agents.

Abstract: The binding of neutral glycolipid GA1 (asialo-GM1) to a broad spectrum of enteric viruses is taught. The glycolipid can be used to pass through the gastrointestinal tract of adults and children to adsorb viral particles and remove them from the body. The glycolipid may be used alone or bound to a non-absorbable resin or matrix.

Abstract: A method for delivering a therapeutic dosage of corticosteroid drug to the lungs, for treating a lung condition or disease. An aqueous suspension of sized liposomes containing the drug in liposome-entrapped form is aerosolized under conditions which produce aerosol particle sizes favoring particle deposition in a selected region of the respiratory tract, and the aerosol is administered in an amount which delivers the thereapeutic dosage level to the selected lung region.

Abstract: A microsuspension system and method for its preparation is disclosed. The microsuspension contain lipospheres, which are solid, water-insoluble microparticles that have a layer of a phospholipid embedded on their surface. The core of the liposphere is a solid substance to be delivered, or a substance to be delivered that is dispersed in an inert solid vehicle, such as a wax.

Abstract: A method of using certain triazine-dione compounds for the control of endo- and ectoparasites of fish and/or insects. The compounds may be combined with aids to form an agent for controlling the endo- or ectoparasites.

Abstract: The present invention relates to the efficient removal of low density lipoprotein cholesterol complex (LDL-C) from whole blood. More specifically, it relates to the use of an immobilized affinity agent on a microporous plasmapheresis membrane. The immobilized affinity agent is polyacrylic acid bound directly and/or through an interaction with silica and/or calcium chloride to a microporous hollow fiber membrane.

Abstract: Methods and devices are disclosed for the delivery of an active factor from an implanted co-culture of an active factor-secreting cell obtained from a first source and an augmentary substance-secreting cell obtained from a second source different from the first source, to a target region in a subject. The co-culture is maintained within a biocompatible, semipermeable membrane in which the augmentary substance secreted by the augmentary substance-producing cells stimulates the active factor-producing cells to secrete active factor. The semipermeable membrane permits the diffusion of the active factor therethrough while excluding detrimental agents present in the extenral environment from gaining access to the co-culture.

Abstract: The invention relates to an oral pharmaceutical multiple units formulation made up of individual cores containing a pharmacologically active substance, the cores being provided with a coating consisting essentially of a polymer that is insoluble in, impermeable to and non-soluble in water and in gastrointestinal fluids, and a water-soluble pore-creating substance, which is randomly distributed in said polymer, whereby said coated cores form units providing an essential zero order diffusion controlled release rate of said active substance. The invention also comprises a method of preparing these formulations.

Abstract: The present invention involves the synthesis and use of new platinum compounds. These new platinum compounds are easy to encapsulate in liposomes at high efficiencies. They are further characterized as platinum (II) four coordinate complex having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are carboxylato monoanions bearing a hydrophobic radical function or a single carboxylato dianion bearing a hydrophobic radical function and R.sub.3 is a vicinal diaminoalkane or vicinal diaminocycloalkane. The complex is substantially soluble in methanol or chloroform and substantially insoluble in water. Said complex may be incorporated into phospholipid liposomes. Such platinum complexes encapsulated in phospholipid liposomes are useful for chemotherapy of platinum complex-sensitive tumors.

Abstract: Aqueous thiocarbonate solutions are stabilized by the addition of base, sulfide and/or polysulfide, and the stability and safety of the more concentrated solutions containing 1 weight percent or more equivalent CS.sub.2 as a thiocarbonate are achieved as reflected by significant reduction of CS.sub.2 partial pressure in such solutions.

Abstract: A novel glycoside, 4.sup.G -alpha-D-glucopyranosyl rutin, is formed by a saccharide-transferring enzyme and glucoamylase in a solution which contains rutin together with glucoamylase. The 4.sup.G -alpha-D-glucopyranosyl rutin formed in such a solution is purified with a synthetic macroreticular resin, and crystallization in an organic solvent yields a complex crystal with the organic solvent. 4.sup.G -Alpha-D-glucopyranosyl rutin exhibits the same molecular absorption coefficient as intact rutin, and is readily water-soluble, substantially tasteless and odorless, and readily hydrolyzable in vivo to exhibit physiological activities inherent to rutin. These render 4.sup.G -alpha-D-glucopyranosyl rutin very useful as a highly-safe, natural yellow coloring agent, antioxidant, stabilizer, quality-improving agent, preventive, remedy, uv-absorbent and deterioration-preventing agent in foods, beverages, tobaccos, cigarets, feeds, pet foods, pharmaceuticals, cosmetics and plastics.

Abstract: The present invention describes a composition consisting of liposomes covalently or non-covalently coupled to the glycoprotein streptavidin. The streptavidin may additionally be coupled to biotinated proteins such as Immunoglobulin G or monoclonal antibodies.The liposomes of the invention may have a transmembrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.

Abstract: A photoresponsive liposome which comprises a compound represented by the following general formula (I): ##STR1## wherein R.sub.1 is an alkyl group; R.sub.2, R.sub.3, R.sub.4 and R.sub.5, which may be the same or different, are selected from the group consisting of an alkyl group, a substituted alkyl group, an alkoxy group, a substituted alkoxy group, a halogen atom and a hydrogen atom; R.sub.6 and R.sub.7, which may be the same or different, are an alkyl group or a hydrogen atom; n is an integer of 1 to 2; and X represents a hydrophilic group, a hydrophobic group or a combination of hydrophilic and hydrophobic groups, bonded through a connecting group, provided that any of these hydrophilic and hydrophobic groups has such properties that the compound represented by the general formula (I) becomes available as a component forming the membrane of liposome.